AU4990696A
(en)
*
|
1995-02-24 |
1996-09-11 |
Nanosystems L.L.C. |
Aerosols containing nanoparticle dispersions
|
US6465016B2
(en)
*
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
US6045829A
(en)
*
|
1997-02-13 |
2000-04-04 |
Elan Pharma International Limited |
Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
UA72189C2
(en)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
|
US8415329B1
(en)
|
1998-05-29 |
2013-04-09 |
Jagotec Ag |
Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
|
EP2266542A3
(en)
*
|
1998-10-01 |
2013-07-31 |
Elan Pharma International Limited |
Controlled release nanoparticulate compositions
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
EP2020229A1
(en)
*
|
1998-11-02 |
2009-02-04 |
Elan Pharma International Limited |
Multiparticulate modified release composition
|
US20040141925A1
(en)
*
|
1998-11-12 |
2004-07-22 |
Elan Pharma International Ltd. |
Novel triamcinolone compositions
|
US6969529B2
(en)
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
US7521068B2
(en)
*
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
BR9915738A
(en)
|
1998-11-20 |
2001-10-02 |
Rtp Pharma Inc |
Microparticles stabilized in dispersible phospholipids
|
DE19856432A1
(en)
*
|
1998-12-08 |
2000-06-15 |
Basf Ag |
Nanoparticulate core-shell systems and their use in pharmaceutical and cosmetic preparations
|
US20090104273A1
(en)
*
|
1999-06-22 |
2009-04-23 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
WO2001021154A2
(en)
*
|
1999-09-21 |
2001-03-29 |
Rtp Pharma Inc. |
Surface modified particulate compositions of biologically active substances
|
DE60028754T2
(en)
|
1999-11-12 |
2007-05-31 |
Abbott Laboratories, Abbott Park |
SOLID DISPERSION WITH RITONAVIR, FENOFIBRATE OR GRISEOFULVIN
|
ES2247054T3
(en)
*
|
2000-01-18 |
2006-03-01 |
Schering Aktiengesellschaft |
PHARMACEUTICAL COMBINATION OF MICRONIZED DROSPIRENONE AND A STROGEN FOR HORMONAL REPLACEMENT THERAPY.
|
EP1265849B1
(en)
*
|
2000-03-23 |
2006-10-25 |
Elan Pharmaceuticals, Inc. |
Compounds and methods to treat alzheimer's disease
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
US6316029B1
(en)
*
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
DE10026698A1
(en)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Self-emulsifying active ingredient formulation and use of this formulation
|
IN192188B
(en)
*
|
2000-06-16 |
2004-03-13 |
Ranbaxy Lab Ltd |
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
JP2004502665A
(en)
*
|
2000-06-30 |
2004-01-29 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
Compounds treating Alzheimer's disease
|
US6846813B2
(en)
*
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
PE20020276A1
(en)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
|
EP1666452A2
(en)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
US7276249B2
(en)
*
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US7998507B2
(en)
*
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
US20030224058A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US20080241070A1
(en)
*
|
2000-09-21 |
2008-10-02 |
Elan Pharma International Ltd. |
Fenofibrate dosage forms
|
US7198795B2
(en)
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
EP1341521B1
(en)
*
|
2000-11-20 |
2009-01-07 |
Elan Pharma International Limited |
Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
US20050048126A1
(en)
*
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US8067032B2
(en)
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US6869617B2
(en)
|
2000-12-22 |
2005-03-22 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US9700866B2
(en)
*
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US20040256749A1
(en)
*
|
2000-12-22 |
2004-12-23 |
Mahesh Chaubal |
Process for production of essentially solvent-free small particles
|
US6884436B2
(en)
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
WO2002072064A2
(en)
*
|
2001-03-09 |
2002-09-19 |
Dow Global Technologies Inc. |
Granular composition comprising an active compound and a cellulose ether and the use thereof
|
CN1255185C
(en)
*
|
2001-05-03 |
2006-05-10 |
弗·哈夫曼-拉罗切有限公司 |
Pharmaceutical dosage form of amorphous nelfinavir mesylate
|
US6976647B2
(en)
*
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
EP1395251A2
(en)
|
2001-06-13 |
2004-03-10 |
Elan Pharmaceuticals, Inc. |
Aminediols as agents for the treatment of alzheimer's disease
|
ATE291899T1
(en)
*
|
2001-06-22 |
2005-04-15 |
Marie Lindner |
HIGH THROUGHPUT SCREENING PROCEDURE (HTS) USING LABORATORY MILLS OR MICROFLUIDICS
|
EP1401399A2
(en)
*
|
2001-06-22 |
2004-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions containing polymer and drug assemblies
|
US6982264B2
(en)
*
|
2001-06-27 |
2006-01-03 |
Elan Pharmaceuticals, Inc. |
Substituted alcohols useful in treatment of Alzheimer's disease
|
US20070213407A1
(en)
*
|
2001-06-29 |
2007-09-13 |
Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc |
Compounds to treat Alzheimer's disease
|
BR0211121A
(en)
*
|
2001-07-10 |
2004-10-26 |
Elan Pharm Inc |
Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt
|
WO2003006013A1
(en)
*
|
2001-07-10 |
2003-01-23 |
Elan Pharmaceuticals, Inc. |
Diaminediols for the treatment of alzheimer's disease
|
US7297553B2
(en)
*
|
2002-05-28 |
2007-11-20 |
Nanosphere, Inc. |
Method for attachment of silylated molecules to glass surfaces
|
MY169670A
(en)
*
|
2003-09-03 |
2019-05-08 |
Tibotec Pharm Ltd |
Combinations of a pyrimidine containing nnrti with rt inhibitors
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
US20030095928A1
(en)
*
|
2001-09-19 |
2003-05-22 |
Elan Pharma International Limited |
Nanoparticulate insulin
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
BR0212833A
(en)
*
|
2001-09-26 |
2004-10-13 |
Baxter Int |
Preparation of submicron sized nanoparticles by dispersion and solvent or liquid phase removal
|
MXPA04003245A
(en)
|
2001-10-04 |
2004-08-11 |
Elan Pharm Inc |
Hydroxypropylamines.
|
ES2292848T3
(en)
*
|
2001-10-12 |
2008-03-16 |
Elan Pharma International Limited |
COMPOSITIONS THAT HAVE A COMBINATION OF CHARACTERISTICS OF IMMEDIATE RELEASE AND CONTROLLED LIBERATION.
|
WO2003034302A1
(en)
*
|
2001-10-15 |
2003-04-24 |
Stark Co., Ltd. |
Content delivery server and content delivery system having the same
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
OA12846A
(en)
*
|
2001-11-08 |
2006-09-15 |
Elan Pharm Inc |
N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives.
|
US20050080141A1
(en)
*
|
2001-11-19 |
2005-04-14 |
Schostarez Heinrich J. |
Amino diols useful in the treatment of alzheimer's disease
|
UA76810C2
(en)
*
|
2001-12-10 |
2006-09-15 |
Мерк Енд Ко., Інк. |
Pharmaceutical compositions of tachikinine receptor antagonist in form of nanoparticles
|
US20030129242A1
(en)
*
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
US20040101566A1
(en)
*
|
2002-02-04 |
2004-05-27 |
Elan Pharma International Limited |
Novel benzoyl peroxide compositions
|
ATE464880T1
(en)
*
|
2002-02-04 |
2010-05-15 |
Elan Pharma Int Ltd |
MEDICINAL NANOPARTICLES WITH LYSOZYME SURFACE STABILIZER
|
US20030215502A1
(en)
*
|
2002-03-20 |
2003-11-20 |
Elan Pharma International Limited |
Fast dissolving dosage forms having reduced friability
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
DE60309300T3
(en)
*
|
2002-03-20 |
2011-02-24 |
Elan Pharma International Ltd. |
NANOPARTICLE COMPOSITIONS OF ANGIOGENIC INHIBITORS
|
US20100226989A1
(en)
*
|
2002-04-12 |
2010-09-09 |
Elan Pharma International, Limited |
Nanoparticulate megestrol formulations
|
US7101576B2
(en)
*
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
US9101540B2
(en)
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
DK1494649T3
(en)
|
2002-04-12 |
2012-04-10 |
Alkermes Pharma Ireland Ltd |
Nanoparticle-MEGESTROLFORMULERINGER
|
US7262208B2
(en)
*
|
2002-04-30 |
2007-08-28 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of Alzheimer's disease
|
AU2003234452A1
(en)
*
|
2002-05-06 |
2003-11-11 |
Elan Pharma International Ltd. |
Nanoparticulate nystatin formulations
|
US20070264348A1
(en)
*
|
2002-05-24 |
2007-11-15 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
CA2488498A1
(en)
*
|
2002-06-10 |
2003-12-18 |
Elan Pharma International Limited |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
EP1531799A1
(en)
*
|
2002-06-10 |
2005-05-25 |
Elan Pharma International Limited |
Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
|
JP4776229B2
(en)
*
|
2002-07-16 |
2011-09-21 |
エラン ファーマ インターナショナル,リミティド |
Stable nanoparticulate active substance liquid dosage composition
|
ATE442130T1
(en)
|
2002-08-12 |
2009-09-15 |
Bend Res Inc |
MEDICINAL PREPARATIONS CONSISTING OF MEDICINAL PRODUCTS IN SEMI-ORDERED FORM AND POLYMERS
|
ES2355723T3
(en)
*
|
2002-09-11 |
2011-03-30 |
Elan Pharma International Limited |
COMPOSITIONS OF ACTIVE AGENT IN GAN STABILIZED NANOPARTICLES.
|
JP2006501936A
(en)
*
|
2002-10-04 |
2006-01-19 |
エラン ファーマ インターナショナル,リミティド |
Gamma irradiation of solid nanoparticle active agents
|
CA2504610C
(en)
*
|
2002-11-12 |
2012-02-21 |
Elan Pharma International Ltd. |
Fast-disintegrating solid dosage forms being not friable and comprising pullulan
|
US20080095806A1
(en)
*
|
2002-11-20 |
2008-04-24 |
Bathurst Ian C |
Composition And Method For Treating Inflammatory Diseases Using Protease Inhibitors
|
PE20040762A1
(en)
*
|
2002-11-27 |
2004-11-06 |
Elan Pharm Inc |
SUBSTITUTED UREAS AND CARBAMATES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE
|
WO2004058216A2
(en)
*
|
2002-12-17 |
2004-07-15 |
Elan Pharma International Ltd. |
Milling microgram quantities of nanoparticulate candidate compounds
|
US7390505B2
(en)
*
|
2003-01-31 |
2008-06-24 |
Elan Pharma International, Ltd. |
Nanoparticulate topiramate formulations
|
US20040208833A1
(en)
*
|
2003-02-04 |
2004-10-21 |
Elan Pharma International Ltd. |
Novel fluticasone formulations
|
WO2005027855A2
(en)
*
|
2003-02-21 |
2005-03-31 |
Jarrow Formulas, Inc. |
Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
|
US8512727B2
(en)
*
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
AR044044A1
(en)
*
|
2003-04-21 |
2005-08-24 |
Elan Pharm Inc |
BENZAMIDA 2-HYDROXI-3-DIAMINOALCANS
|
AR044043A1
(en)
*
|
2003-04-21 |
2005-08-24 |
Elan Pharm Inc |
FENACILO 2-HIDROXI-3-DIAMINOALCANOS
|
WO2004105809A1
(en)
*
|
2003-05-22 |
2004-12-09 |
Elan Pharma International Ltd. |
Sterilization of dispersions of nanoparticulate active agents with gamma radiation
|
CA2540695A1
(en)
*
|
2003-06-24 |
2004-12-29 |
Baxter International Inc. |
Specific delivery of drugs to the brain
|
US8986736B2
(en)
*
|
2003-06-24 |
2015-03-24 |
Baxter International Inc. |
Method for delivering particulate drugs to tissues
|
NZ544585A
(en)
*
|
2003-07-11 |
2008-04-30 |
Hoffmann La Roche |
Saquinavir mesylate oral dosage form
|
JP2007501839A
(en)
*
|
2003-08-08 |
2007-02-01 |
エラン ファーマ インターナショナル リミテッド |
New metaxalone composition
|
GB0319797D0
(en)
*
|
2003-08-26 |
2003-09-24 |
Leuven K U Res & Dev |
Particle size reduction of poorly soluble drugs
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US7879360B2
(en)
*
|
2003-11-05 |
2011-02-01 |
Elan Pharma International, Ltd. |
Nanoparticulate compositions having a peptide as a surface stabilizer
|
WO2005055928A2
(en)
*
|
2003-12-02 |
2005-06-23 |
The Ohio State University Research Foundation |
Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
|
WO2005070407A1
(en)
*
|
2004-01-21 |
2005-08-04 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using aspartyl-protease inihibitors
|
BRPI0507308A
(en)
*
|
2004-01-29 |
2007-06-26 |
Baxter Int |
nanosuspensions of antiretroviral agents for increased central nervous system delivery
|
WO2005087752A2
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
EP1734961A2
(en)
*
|
2004-03-09 |
2006-12-27 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
|
CA2558249A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
|
JP2007528400A
(en)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
Substituted hydroxyethylamine aspartic protease inhibitors
|
WO2005117997A1
(en)
*
|
2004-06-01 |
2005-12-15 |
The Ohio State University |
Ligands having metal binding ability and targeting properties
|
KR20070037444A
(en)
*
|
2004-06-15 |
2007-04-04 |
백스터 인터내셔널 인코포레이티드 |
Ex-vivo application of solid microparticulate therapeutic agents
|
US8377948B2
(en)
*
|
2004-06-21 |
2013-02-19 |
The Ohio State University Research Foundation |
Antitumor agents and methods of their use
|
CA2572775A1
(en)
*
|
2004-07-09 |
2006-01-26 |
Elan Pharmaceuticals, Inc. |
Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
|
WO2006010095A2
(en)
*
|
2004-07-09 |
2006-01-26 |
Elan Pharmaceuticals Inc. |
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
|
CA2577392A1
(en)
*
|
2004-08-27 |
2006-03-09 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
|
RU2007106036A
(en)
*
|
2004-08-31 |
2008-10-10 |
Пфайзер Продактс Инк. (Us) |
ANTIBODY TO CD40: DRUG AND METHODS
|
EP2623095A1
(en)
*
|
2004-11-16 |
2013-08-07 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
UA89513C2
(en)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Nanoparticulate raloxifene hydrochloride composition
|
US20080145430A1
(en)
*
|
2004-12-08 |
2008-06-19 |
Santipharp Panmai |
Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
|
KR20070116581A
(en)
*
|
2004-12-15 |
2007-12-10 |
엘란 파마 인터내셔널 리미티드 |
Nanoparticulate tacrolimus formulations
|
WO2006069098A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Elan Pharma International Ltd. |
Nanoparticulate bicalutamide formulations
|
CA2594332A1
(en)
*
|
2005-01-06 |
2006-07-13 |
Elan Pharma International Ltd. |
Nanoparticulate candesartan formulations
|
CA2597716A1
(en)
|
2005-02-15 |
2006-08-24 |
Elan Pharma International Limited |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
EP1855651A4
(en)
*
|
2005-03-03 |
2011-06-15 |
Elan Pharma Int Ltd |
Nanoparticulate compositions of heterocyclic amide derivatives
|
WO2006099121A2
(en)
*
|
2005-03-10 |
2006-09-21 |
Elan Pharma International Limited |
Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
|
AU2006225117A1
(en)
*
|
2005-03-16 |
2006-09-21 |
Elan Pharma International Limited |
Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
|
EA200701997A1
(en)
*
|
2005-03-17 |
2008-02-28 |
Элан Фарма Интернэшнл Лтд. |
COMPOSITION OF BISPHOSPHONATE NANOPARTICLES
|
WO2006102494A2
(en)
*
|
2005-03-23 |
2006-09-28 |
Elan Pharma International Limited |
Nanoparticulate corticosteroid and antihistamine formulations
|
JP2008535924A
(en)
*
|
2005-04-12 |
2008-09-04 |
エラン ファーマ インターナショナル リミテッド |
Nanoparticulate quinazoline derivative formulation
|
WO2006110809A2
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International, Limited |
Nanoparticulate lipase inhibitor formulations
|
WO2006110802A1
(en)
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising cyclosporine
|
EP1874267A1
(en)
*
|
2005-04-13 |
2008-01-09 |
Pfizer Products Inc. |
Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
|
WO2006132752A1
(en)
*
|
2005-05-10 |
2006-12-14 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising vitamin k2
|
JP2008540546A
(en)
*
|
2005-05-10 |
2008-11-20 |
エラン ファーマ インターナショナル リミテッド |
Nanoparticulate clopidogrel formulation
|
US20100028439A1
(en)
*
|
2005-05-23 |
2010-02-04 |
Elan Pharma International Limited |
Nanoparticulate stabilized anti-hypertensive compositions
|
WO2006133045A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Elan Pharma International, Limited |
Nanoparticulate benidipine compositions
|
CN101232870A
(en)
*
|
2005-06-03 |
2008-07-30 |
伊兰制药国际有限公司 |
Nanoparticulate imatinib mesylate formulations
|
CN101262860A
(en)
*
|
2005-06-03 |
2008-09-10 |
伊兰制药国际有限公司 |
Nanoparticulate acetaminophen formulations
|
EP1954253A4
(en)
|
2005-06-08 |
2011-07-27 |
Elan Pharma Int Ltd |
Nanoparticulate and controlled release compositions comprising cefditoren
|
DE602006010070D1
(en)
*
|
2005-06-09 |
2009-12-10 |
Elan Pharma Int Ltd |
NANOPARTICULAR EBASINE FORMULATIONS
|
CN101237868A
(en)
*
|
2005-06-13 |
2008-08-06 |
伊兰制药国际有限公司 |
Nanoparticulate clopidogrel and aspirin combination formulations
|
US20060280787A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Baxter International Inc. |
Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
|
EP1906973A2
(en)
*
|
2005-06-14 |
2008-04-09 |
Baxter International Inc. |
Pharmaceutical formulations for minimizing drug-drug interactions
|
WO2006138421A2
(en)
*
|
2005-06-15 |
2006-12-28 |
Elan Pharma International Limited |
Nanoparticulate azelnidipine formulations
|
EP1904041A2
(en)
*
|
2005-07-07 |
2008-04-02 |
Elan Pharma International Limited |
Nanoparticulate clarithromycin formulations
|
WO2007011989A2
(en)
*
|
2005-07-15 |
2007-01-25 |
Map Pharmaceuticals, Inc. |
Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
|
EP1937217A2
(en)
*
|
2005-09-13 |
2008-07-02 |
Elan Pharma International Limited |
Nanoparticulate tadalafil formulations
|
WO2007035348A2
(en)
*
|
2005-09-15 |
2007-03-29 |
Elan Pharma International, Limited |
Nanoparticulate aripiprazole formulations
|
WO2007047306A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
KR20080080119A
(en)
*
|
2005-11-15 |
2008-09-02 |
백스터 인터내셔널 인코포레이티드 |
Compositions of lipoxygenase inhibitors
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
US20070281011A1
(en)
*
|
2006-05-30 |
2007-12-06 |
Elan Pharma International Ltd. |
Nanoparticulate posaconazole formulations
|
HUE038797T2
(en)
*
|
2006-06-23 |
2018-11-28 |
Janssen Sciences Ireland Uc |
Aqueous suspensions of tmc278
|
US20080213374A1
(en)
*
|
2006-07-10 |
2008-09-04 |
Elan Pharma International Limited |
Nanoparticulate sorafenib formulations
|
BRPI0714173A2
(en)
*
|
2006-07-12 |
2012-12-25 |
Elan Pharma Int Ltd |
stable nanoparticulate composition, methods for preparing the composition, for preventing and / or treating disease conditions, symptoms, syndromes and conditions of the central nervous system, for improving or maintaining bioavailability of modafinil, and for treating neurologically based disorder, pharmaceutical composition, and dosage form
|
KR20090091321A
(en)
*
|
2006-11-28 |
2009-08-27 |
마리누스 파마슈티컬스 |
Nanoparticulate formulations and methods for the making and use thereof
|
US20090152176A1
(en)
*
|
2006-12-23 |
2009-06-18 |
Baxter International Inc. |
Magnetic separation of fine particles from compositions
|
AR065720A1
(en)
*
|
2007-03-14 |
2009-06-24 |
Tibotec Pharm Ltd |
RECONSTITUTION POWERS THAT INCLUDE RILPIVIRINE DISPERSED IN CERTAIN POLYMERS. USE. PROCESS.
|
US8722736B2
(en)
*
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
US8426467B2
(en)
*
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US20080293814A1
(en)
*
|
2007-05-22 |
2008-11-27 |
Deepak Tiwari |
Concentrate esmolol
|
US8642062B2
(en)
|
2007-10-31 |
2014-02-04 |
Abbott Cardiovascular Systems Inc. |
Implantable device having a slow dissolving polymer
|
JP2011520779A
(en)
*
|
2008-03-21 |
2011-07-21 |
エラン・ファルマ・インターナショナル・リミテッド |
Compositions and methods of use for site-specific delivery of imatinib
|
GB0818403D0
(en)
*
|
2008-10-08 |
2008-11-12 |
Univ Leuven Kath |
Aqueous electrophoretic deposition
|
WO2010040648A2
(en)
*
|
2008-10-06 |
2010-04-15 |
Katholieke Universiteit Leuven, K.U.Leuven R&D |
Functional layers of biomolecules and living cells, and a novel system to produce such
|
DK3045043T3
(en)
|
2009-02-26 |
2020-08-03 |
Relmada Therapeutics Inc |
ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINANE WITH EXTENDED RELEASE AND METHOD OF USE
|
SG175137A1
(en)
*
|
2009-04-09 |
2011-11-28 |
Alkermes Pharma Ireland Ltd |
Drug delivery composition
|
US20100291221A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Robert Owen Cook |
Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
|
FR2945950A1
(en)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
ANTICANCER NANOPARTICLE COMPOSITIONS AND METHODS FOR PREPARING THE SAME
|
WO2010138539A2
(en)
|
2009-05-27 |
2010-12-02 |
Elan Pharma International Ltd. |
Reduction of flake-like aggregation in nanoparticulate active agent compositions
|
WO2010146407A1
(en)
|
2009-06-19 |
2010-12-23 |
Nanoform Hungary Ltd. |
Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
|
KR101845811B1
(en)
*
|
2009-09-22 |
2018-05-18 |
얀센 알 앤드 디 아일랜드 |
Treatment and Prevention of HIV Infection
|
DK2605655T3
(en)
|
2010-08-19 |
2019-02-04 |
Buck Institute For Age Res |
METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
|
EP2635260A4
(en)
*
|
2010-11-02 |
2014-07-09 |
Univ Nebraska |
Compositions and methods for the delivery of therapeutics
|
AU2013246926B2
(en)
|
2012-04-13 |
2016-07-21 |
Glaxosmithkline Intellectual Property Development Limited |
Aggregate particles
|
EP2890370B1
(en)
|
2012-08-31 |
2019-10-09 |
The Regents of the University of California |
Agents useful for treating obesity, diabetes and related disorders
|
WO2015108945A2
(en)
|
2014-01-14 |
2015-07-23 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the delivery of therapeutics
|
WO2016057866A1
(en)
|
2014-10-09 |
2016-04-14 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the delivery of therapeutics
|
US10166197B2
(en)
|
2015-02-13 |
2019-01-01 |
St. John's University |
Sugar ester nanoparticle stabilizers
|
EP3288957A4
(en)
|
2015-05-01 |
2019-01-23 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
US10669305B2
(en)
*
|
2015-10-13 |
2020-06-02 |
Hetero Labs Limited |
C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors
|
TWI678203B
(en)
*
|
2016-05-31 |
2019-12-01 |
中裕新藥股份有限公司 |
A long acting pharmaceutical composition of protease inhibitor
|
US11839623B2
(en)
|
2018-01-12 |
2023-12-12 |
Board Of Regents Of The University Of Nebraska |
Antiviral prodrugs and formulations thereof
|
CA3132832A1
(en)
|
2018-04-09 |
2019-10-17 |
Howard E. Gendelman |
Antiviral prodrugs and formulations thereof
|